Jonathan Young compensation by year
Akero Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $449,000 | $471,000 | $490,000 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $824,425 | $645,715 | $710,289 |
| Option awards | $2,556,818 | $2,122,820 | $1,617,885 |
| Non-equity incentive | $314,300 | $201,353 | $220,500 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $0 | $0 | $0 |
| Total | $4,144,543 | $3,440,888 | $3,038,674 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Akero Therapeutics, Inc. DEF 14A filed April 28, 2025, accession 0000950170-25-058964, and prior-year filings.
How this page was built: the Akero Therapeutics, Inc. filed document, accession 0000950170-25-058964. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 24,373 | $678,057 | — |
| RSU | 24,300 | $676,026 | — |
| RSU | 9,598 | $267,016 | — |
| Option | 21,806 | — | $21.10 |
| Option | 43,189 | — | $42.95 |
| Option | 109,678 | — | $19.87 |
| Option | 73,700 | — | $29.23 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Akero Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
40 Form 4 lines since the FY2024 proxy (filed April 28, 2025)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-12-09 | Disposition to the issuer | — | 20,000 | — | 0 |
| 2025-12-09 | Disposition to the issuer derivative | — | 29,073 | — | 0 |
| 2025-12-09 | Disposition to the issuer | — | 152,616 | — | 0 |
| 2025-12-09 | Disposition to the issuer | — | 20,000 | — | 0 |
| 2025-12-09 | Disposition to the issuer derivative | — | 70,279 | — | 0 |
| 2025-12-09 | Disposition to the issuer derivative | — | 44,982 | — | 0 |
| 2025-12-09 | Disposition to the issuer derivative | — | 3,421 | — | 0 |
| 2025-12-09 | Disposition to the issuer | — | 20,000 | — | 0 |
The 8 most recent of 40 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Akero Therapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Andrew Cheng | President and Chief Executive Officer | $10,465,855 |
| Scott Gangloff | Chief Technology Officer | $6,112,056 |
| William White | Chief Financial Officer | $3,067,674 |
| Catriona Yale | Chief Development Officer | $3,044,474 |
| Jonathan Young · this page | Chief Operating Officer | $3,038,674 |
Jonathan Young's compensation dossier, Akero Therapeutics
You have read Jonathan Young's totals and holdings. The dossier adds each equity grant Akero Therapeutics disclosed for Jonathan Young and Akero Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Akero Therapeutics compensation record
free company briefThis page is one person within Akero Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Akero Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Akero Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Akero Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.